CN1655820A - Pde5抑制剂与ace抑制剂的药物组合 - Google Patents

Pde5抑制剂与ace抑制剂的药物组合 Download PDF

Info

Publication number
CN1655820A
CN1655820A CNA038118262A CN03811826A CN1655820A CN 1655820 A CN1655820 A CN 1655820A CN A038118262 A CNA038118262 A CN A038118262A CN 03811826 A CN03811826 A CN 03811826A CN 1655820 A CN1655820 A CN 1655820A
Authority
CN
China
Prior art keywords
inhibitor
pde5
hypertension
sldenafil
ace
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038118262A
Other languages
English (en)
Chinese (zh)
Inventor
D·N·A·福克斯
B·休吉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Pfizer Inc
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0211919A external-priority patent/GB0211919D0/en
Priority claimed from GB0229784A external-priority patent/GB0229784D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of CN1655820A publication Critical patent/CN1655820A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA038118262A 2002-05-23 2003-05-09 Pde5抑制剂与ace抑制剂的药物组合 Pending CN1655820A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0211919A GB0211919D0 (en) 2002-05-23 2002-05-23 Novel combination
GB0211919.6 2002-05-23
GB0229784.4 2002-12-20
GB0229784A GB0229784D0 (en) 2002-12-20 2002-12-20 Novel combination

Publications (1)

Publication Number Publication Date
CN1655820A true CN1655820A (zh) 2005-08-17

Family

ID=29585817

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038118262A Pending CN1655820A (zh) 2002-05-23 2003-05-09 Pde5抑制剂与ace抑制剂的药物组合

Country Status (18)

Country Link
EP (1) EP1506015A2 (pt)
JP (1) JP2005529927A (pt)
KR (1) KR20050004195A (pt)
CN (1) CN1655820A (pt)
AR (1) AR040090A1 (pt)
AU (1) AU2003223071A1 (pt)
BR (1) BR0311191A (pt)
CA (1) CA2485984A1 (pt)
IL (1) IL164975A0 (pt)
MX (1) MXPA04010951A (pt)
NO (1) NO20045517L (pt)
PA (1) PA8574201A1 (pt)
PE (1) PE20040514A1 (pt)
PL (1) PL374198A1 (pt)
RU (1) RU2004133973A (pt)
TW (1) TW200407153A (pt)
UY (1) UY27816A1 (pt)
WO (1) WO2003099194A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
GB0318094D0 (en) * 2003-08-01 2003-09-03 Pfizer Ltd Novel combination
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (en) * 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
FR2902009B1 (fr) * 2006-06-13 2012-12-07 Bioprojet Soc Civ Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire
US20100324037A1 (en) * 2006-08-24 2010-12-23 Surface Logix, Inc. Pharmacokinetically improved compounds
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
ES2924478T3 (es) 2012-03-15 2022-10-07 Boehringer Ingelheim Vetmedica Gmbh Formulación de comprimidos farmacéuticos para el sector médico veterinario, método de producción y uso de los mismos
CN113181110A (zh) 2013-07-19 2021-07-30 勃林格殷格翰动物保健有限公司 含有防腐的醚化的环糊精衍生物的液体水性药物组合物
WO2015082389A1 (en) 2013-12-04 2015-06-11 Boehringer Ingelheim Vetmedica Gmbh Improved pharmaceutical compositions of pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316906A (en) * 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
HU230154B1 (hu) * 1997-11-12 2015-09-28 Bayer Intellectual Property Gmbh Eljárás 2-es helyzetben fenil-szubszituenst hordozó imidazo-triazinon-származékok előállítására
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
CZ20021151A3 (cs) * 1999-10-11 2003-03-12 Pfizer Inc. 5-(2-substituovaný-5-heterocyklylsulfonylpyrid-3-yl)-dihydropyrazolo[4,3-d]-pyrimidin-7-ony jako inhibitory fosfodiesterasy

Also Published As

Publication number Publication date
NO20045517L (no) 2004-12-17
AU2003223071A1 (en) 2003-12-12
KR20050004195A (ko) 2005-01-12
CA2485984A1 (en) 2003-12-04
WO2003099194A2 (en) 2003-12-04
EP1506015A2 (en) 2005-02-16
RU2004133973A (ru) 2005-09-10
BR0311191A (pt) 2005-03-01
PA8574201A1 (es) 2003-12-19
JP2005529927A (ja) 2005-10-06
PL374198A1 (en) 2005-10-03
WO2003099194A3 (en) 2004-06-03
IL164975A0 (en) 2005-12-18
UY27816A1 (es) 2003-12-31
AR040090A1 (es) 2005-03-16
MXPA04010951A (es) 2005-06-08
PE20040514A1 (es) 2004-08-24
TW200407153A (en) 2004-05-16

Similar Documents

Publication Publication Date Title
Wang et al. BI-1356
CN1196487C (zh) 单位剂量形式
JP2007169278A (ja) Ｌｕｔｓ処置用の医薬組合せ
CN1655820A (zh) Pde5抑制剂与ace抑制剂的药物组合
CN1282248A (zh) 阳萎的联合治疗
TWI741286B (zh) 治療癌症之方法
US20210177845A1 (en) Pde9 inhibitors for treating sickle cell disease
CN106999495A (zh) Tlr抑制剂和布鲁顿酪氨酸激酶抑制剂组合
CN101433717A (zh) 含有食糜酶抑制剂和ace抑制剂作为有效成分的药物
KR20120104523A (ko) 디펩티딜 펩티다제―４ 억제제와 피오글리타존의 조합물의 제약 조성물
CN1471397A (zh) 治疗偏头痛的方法
JP2009520806A (ja) ＰＤＥ−５阻害薬と５−α還元酵素阻害薬の医薬組合せ
CN1446091A (zh) 用pde5抑制剂进行勃起功能障碍的每日治疗
CN1662257A (zh) Pde5抑制剂与血管紧张肽ⅱ受体拮抗剂的联用药物
Hegde et al. To market, to market–2005
CN114728003A (zh) 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合
CN101711153A (zh) 用于治疗听觉损伤的pde抑制剂
RU2533560C2 (ru) Фармацевтическая композиция для лечения диабета 2 типа
US20040132731A1 (en) Novel combination
US20040077624A1 (en) Novel combination
US20050059660A1 (en) Novel combination
Bhardwaj et al. Identification of Dipeptidyl peptidase-4 (DPP-4) inhibitors as Potential Antidiabetic agents using Molecular docking study
WO2011009360A1 (zh) 治疗哺乳动物包括人2型糖尿病的药物组合物
TWI494313B (zh) 治療包括人類之哺乳動物中第２型糖尿病的醫藥組成物
CN101489562A (zh) 用于治疗脊髓增生病的jak抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1076380

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1076380

Country of ref document: HK